Polycythemia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(18 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Polycythemia}}
{{Polycythemia}}
{{CMG}}{{AE}}{{Debduti}}
{{CMG}} ; {{AE}} {{Debduti}}


==Overview==
==Overview==
*Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
 
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The [[incidence]] of [[polycythemia vera]] is approximately 1.9 per 100,000 individuals in the United States.<ref name="pmid1730276">{{cite journal| author=Berglund S, Zettervall O| title=Incidence of polycythemia vera in a defined population. | journal=Eur J Haematol | year= 1992 | volume= 48 | issue= 1 | pages= 20-6 | pmid=1730276 | doi=10.1111/j.1600-0609.1992.tb01788.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1730276  }}</ref><ref name="pmid11073167">{{cite journal| author=Ridell B, Carneskog J, Wedel H, Vilén L, Høgh Dufva I, Mellqvist UH | display-authors=etal| title=Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992. | journal=Eur J Haematol | year= 2000 | volume= 65 | issue= 4 | pages= 267-71 | pmid=11073167 | doi=10.1034/j.1600-0609.2000.065004267.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11073167  }}</ref><ref name="pmid32491592">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume=  | issue=  | pages=  | pmid=32491592 | doi= | pmc= | url= }}</ref>
*Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females.


===Prevalence===
===Prevalence===
*The prevalence of polycythemia vera in the 7 MM countries was 283,442 in 2017.
*Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref>


*The [[prevalence]] of [[Polycythemia vera|polycythemia vera i]]<nowiki/>n the 7 MM countries was 283,442 in 2017.
*[[Prevalence]] of [[polycythemia vera]] was the highest in the US in 2017 at 157,290, out of which 62,916 cases were [[asymptomatic]] and 94,374 were [[symptomatic]].
*22 cases per 100,000 people.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
 
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
*4-year [[Mortality rate|mortality]] rate is >10%.
*On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
*[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often.<ref name="pmid23281576">{{cite journal| author=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH | display-authors=etal| title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. | journal=Eur J Haematol | year= 2013 | volume= 90 | issue= 3 | pages= 228-36 | pmid=23281576 | doi=10.1111/ejh.12064 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23281576  }}</ref>
*[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]].


===Age===
===Age===
*It has been noted that PV is more common in the age group >75. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref>
*Median age of diagnosis is 60. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref>


*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*It has been noted that PV is more common in the age group >75.<ref name="pmid8039752">{{cite journal| author=Frezzato M, Ruggeri M, Castaman G, Rodeghiero F| title=Polycythemia vera and essential thrombocythemia in young patients. | journal=Haematologica | year= 1993 | volume= 78 | issue= 6 Suppl 2 | pages= 11-7 | pmid=8039752 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8039752  }}</ref>
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
*Median age of diagnosis is 60.<ref name="pmid324915922">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume=  | issue=  | pages=  | pmid=32491592 | doi= | pmc= | url= }}</ref>
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
 
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
*Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians.


===Gender===
===Gender===
*Generally, there is no sex predeliction.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref>
*In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref>
===Region===
*The majority of [disease name] cases are reported in [geographical region].


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
*Generally, there is no sex predilection.<ref name="pmid324915923">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume=  | issue=  | pages=  | pmid=32491592 | doi= | pmc= | url= }}</ref>
*In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females.


===Developed Countries===
===Region===


===Developing Countries===
*Incidence of cases is higher in the United States and Europe than in Japan.<ref name="pmid324915924">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume= | issue=  | pages=  | pmid=32491592 | doi= | pmc= | url= }}</ref><ref name="pmid16673273">{{cite journal |vauthors=Johansson P |title=Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia |journal=Semin Thromb Hemost |volume=32 |issue=3 |pages=171–3 |date=April 2006 |pmid=16673273 |doi=10.1055/s-2006-939430 |url=}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
{{WS}}
{{WH}}
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
Line 52: Line 53:
[[Category:Blood disorders]]
[[Category:Blood disorders]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
{{WS}}
{{WH}}

Latest revision as of 16:02, 5 March 2021

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia epidemiology and demographics

CDC on Polycythemia epidemiology and demographics

Polycythemia epidemiology and demographics in the news

Blogs on Polycythemia epidemiology and demographics

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

  • Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies.

Epidemiology and Demographics

Incidence

  • The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States.[1][2][3]
  • Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females.

Prevalence

Case-fatality rate/Mortality rate

  • 4-year mortality rate is >10%.
  • On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
  • Comorbidities such as cardiovascular diseases, other blood, and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc. accounted for more deaths more often.[4]
  • Thrombotic complications were the most common cause of death followed by hematologic malignancy.

Age

  • It has been noted that PV is more common in the age group >75.[5]
  • Median age of diagnosis is 60.[6]

Race

  • Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians.

Gender

  • Generally, there is no sex predilection.[7]
  • In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females.

Region

  • Incidence of cases is higher in the United States and Europe than in Japan.[8][9]

References

  1. ↑ Berglund S, Zettervall O (1992). "Incidence of polycythemia vera in a defined population". Eur J Haematol. 48 (1): 20–6. doi:10.1111/j.1600-0609.1992.tb01788.x. PMID 1730276.
  2. ↑ Ridell B, Carneskog J, Wedel H, Vilén L, Høgh Dufva I, Mellqvist UH; et al. (2000). "Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992". Eur J Haematol. 65 (4): 267–71. doi:10.1034/j.1600-0609.2000.065004267.x. PMID 11073167.
  3. ↑ "StatPearls". 2021. PMID 32491592 Check |pmid= value (help).
  4. ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH; et al. (2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur J Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
  5. ↑ Frezzato M, Ruggeri M, Castaman G, Rodeghiero F (1993). "Polycythemia vera and essential thrombocythemia in young patients". Haematologica. 78 (6 Suppl 2): 11–7. PMID 8039752.
  6. ↑ "StatPearls". 2021. PMID 32491592 Check |pmid= value (help).
  7. ↑ "StatPearls". 2021. PMID 32491592 Check |pmid= value (help).
  8. ↑ "StatPearls". 2021. PMID 32491592 Check |pmid= value (help).
  9. ↑ Johansson P (April 2006). "Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia". Semin Thromb Hemost. 32 (3): 171–3. doi:10.1055/s-2006-939430. PMID 16673273.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Polycythemia_epidemiology_and_demographics&oldid=1693303"